<DOC>
	<DOCNO>NCT00782379</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine , busulfan , cyclophosphamide , donor peripheral blood stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving high-dose cyclophosphamide together tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well combination chemotherapy work give together donor stem cell transplant , follow tacrolimus , mycophenolate mofetil , high-dose cyclophosphamide , treat patient high-risk hematologic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Donor Stem Cell Transplant , Tacrolimus , Mycophenolate Mofetil , Cyclophosphamide Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate incidence graft rejection severe graft-versus-host disease myeloablative HLA-mismatched peripheral blood stem cell transplantation ( PBSCT ) first-degree relative patient high-risk hematologic malignancy . Secondary - To estimate overall survival , relapse , non-relapse mortality , event-free survival patient . - To characterize additional hematologic non-hematologic toxicity myeloablative haploidentical PBSCT . - To characterize donor hematopoietic chimerism peripheral blood stem cell PBSCT . OUTLINE : - Preparative regimen : Patients receive fludarabine phosphate IV 30 minute day -7 -2 , busulfan IV 3 hour day -7 -4 , cyclophosphamide IV 1-2 hour day -3 -2 . - Allogeneic peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo infusion unmanipulated peripheral blood stem cell day 0 . - Post-transplant regimen : Patients receive high-dose cyclophosphamide IV 1-2 hour day 3 4 , tacrolimus IV 24 hour orally twice daily day 5-180 , oral mycophenolate mofetil 3 time daily day 5-34 followed taper day 90 . Treatment continue absence disease progression clinically significant graft-vs-host disease . After completion PBSCT , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow highrisk hematologic malignancy : Chronic myelogenous leukemia meet one follow criterion : Disease chronic phase resistant available tyrosine kinase inhibitor Disease accelerate phase Disease blast crisis enter second chronic phase induction chemotherapy Acute myelogenous leukemia meeting follow criterion : Marrow blast &lt; 5 % persistence minimal residual disease flow cytometry , cytogenetics , FISH Must meet one follow criterion : Disease second subsequent complete remission Primary induction chemotherapy failure disease subsequently enter complete remission Disease first complete remission poorrisk cytogenetics arise precede hematological disease Myelodysplastic syndrome meeting least one follow criterion : Treatmentrelated Monosomy 7 complex cytogenetics International prognostic scoring system score ≥ 1.5 Chronic myelomonocytic leukemia Acute lymphocytic leukemia lymphoblastic lymphoma meeting follow criterion : Marrow blast &lt; 5 % persistence minimal residual disease flow cytometry , cytogenetics , FISH Must meet one follow criterion : Disease second subsequent complete remission Acute lymphocytic leukemia poorrisk karyotype [ e.g. , ( 9 ; 22 ) bcrabl fusion , ( 4 ; 11 ) , MLL translocation ] first complete remission Chronic lymphocytic leukemia prolymphocytic leukemia meeting follow criterion : Previously treat disease either relapse failed respond adequately conventionaldose therapy include purine analog In opinion transplant physician , unlikely benefit reduce intensity transplantation due presence one highrisk feature ( i.e. , bulky tumor mass , B symptom , and/or inadequate response salvage chemotherapy ) Hodgkin nonHodgkin lymphoma ( include lowgrade , mantle cell , intermediategrade/diffuse disease ) meeting follow criterion : Previously treat disease either relapse failed respond adequately conventionaldose therapy autologous transplantation In opinion transplant physician , unlikely benefit reduce intensity transplantation due presence one highrisk feature ( i.e. , bulky tumor mass , B symptom , and/or inadequate response salvage chemotherapy ) NOTE : A new classification scheme adult nonHodgkin lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . No available match relate unrelated donor OR match relate unrelated donor available time frame necessary perform transplant Availability firstdegree relative ( parent , child , sibling ) match 3/65/6 locus ( HLAA , B , DR ) Donor must willing donate mobilized peripheral blood stem cell No positive HLA crossmatch hostvsgraft direction high titer donorspecific antibodies PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 2 mg/dL ( unless due hemolysis , Gilbert syndrome , primary malignancy ) Creatinine &lt; 2 mg/dL OR creatinine clearance ≥ 40 mL/min Not pregnant Fertile patient must use effective contraception LVEF ( Left ventriculr ejection fraction ) ≥ 45 % FEV_1 force vital capacity ≥ 50 % predict No HIV positivity No debilitate medical psychiatric illness would preclude give informed consent receive optimal treatment followup PRIOR CONCURRENT THERAPY : See Disease Characteristics No immunosuppressive agent ≤ 24 hour completion posttransplant cyclophosphamide ( include steroid antiemetic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>